While mirabegron has provided critical proof-of-concept for β3-AR–mediated BAT activation in humans, its dose-limiting cardiovascular effects have constrained broader therapeutic application in metabolic disease [49,167,169]. The gene discussed is ADRB3; the disease is metabolic disease.